Roche’s Etrolizumab Failure ‘Removes Big Pipeline Opportunity’
Topline Phase III Data Showed Mixed Induction Results, Maintenance Miss
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.